Advocating vaccination of adults aged 60 years and older in western Europe: Statement by the joint vaccine working group of the european union geriatric medicine society and the international association of gerontology and geriatrics-European region

Rejuvenation Research

Volumn 12, Issue 2, 2009, Pages 127-135

  Michel, Jean Pierre ^a   Chidiac, Christian ^b   Grubeck Loebenstein, Beatrix ^c   Johnson, Robert W ^d   Lambert, Paul Henri ^a   Maggi, Stefania ^e   Moulias, Robert ^f   Nicholson, Karl ^g   Werner, Hans ^h  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b CROIX ROUSSE HOSPITAL   (France)

^c Institute for Biomedical Aging Research   (Austria)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e Center on Aging   (Italy)

^f HÔPITAL CHARLES FOIX   (France)

^g LEICESTER ROYAL INFIRMARY   (United Kingdom)

^h Ev Krankenhaus Elisabethenstift   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA VACCINE; INFLUENZA VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID; VARICELLA ZOSTER VACCINE;

AGED; AGING; ANTIBODY RESPONSE; ARTICLE; DIPHTHERIA; ELDERLY CARE; HEALTH CARE POLICY; HERPES ZOSTER; HUMAN; IMMUNITY; INFLUENZA; PERTUSSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; T LYMPHOCYTE; TETANUS; VACCINATION; WESTERN EUROPE;

AGED; COMMUNICABLE DISEASES; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; EUROPE; EUROPEAN UNION; GERIATRICS; HUMANS; IMMUNITY; INTERNATIONAL COOPERATION; PATIENT COMPLIANCE; SOCIETIES, MEDICAL; VACCINATION; VACCINES;

EID: 66249135655     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2008.0813     Document Type: Article

References (90)

1. Siegrist CA. [Vaccinology update 2005: A new category of recommendations for optimal vaccine protection]. Rev Med Suisse 2006;2:67-70.
2. Zimmerman RK, Middleton DB, Burns IT, Clover RD, Kimmel SR. Routine vaccines across the life span, 2007. J Fam Pract 2007;56:S18-S37, C1-C3.
3. Vitek CR, Wharton M. Diphtheria in the former Soviet Union: Reemergence of a pandemic disease. Emerg Infect Dis 1998;4:539-550.
4. de Greeff SC, Mooi FR, Schellekens JF, de Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J 2008;27:218-223.
5. Kretsinger K, Broder KR, Cortese MM et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006;55: 1-37.
6. Htwe TH, Mushtaq A, Robinson SB, Rosher RB, Khardori N. Infection in the elderly. Infect Dis Clin NAm 2007;21: 711-743.
7. Liang SY, Mackowiak PA. Infections in the elderly. Clin Geriatr Med 2007;23:441-456, viii.
8. High K. Immunizations in older adults. Clin Geriatr Med 2007;23:669-685, viii-ix.
9. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001:systematic analysis of population health data. Lancet 2006;367:1747-1757.
10. Yoshikawa TT. Perspective: Aging and infectious diseases: past, present, and future. J Infect Dis 1997;176:1053-1057.
11. Castro L, Goncalves G, Catarino J. [Reported cases of tetanus in the North of Portugal (1993-2002). Missed opportunities for vaccination]. Acta Med Port 2004;17:225-230.
12. Rushdy AA, White JM, Ramsay ME, Crowcroft NS. Tetanus in England and Wales, 1984-2000. Epidemiol Infect 2003;130:71-77.
13. Zielinski A. [Tetanus in 1998]. Przegl Epidemiol 2000;54: 151-156.
14. Zielinski A. [Tetanus in Poland in 1999]. Przegl Epidemiol 2001;55:137-140.
15. Zielinski A. [Tetanus in Poland in 2000]. Przegl Epidemiol 2002;56:335-338.
16. Zielinski A. [Tetanus in Poland in 2002]. Przegl Epidemiol 2004;58:139-142.
17. Zielinski A. [Tetanus in Poland in 2003]. Przegl Epidemiol 2005;59:309-312.
18. Zielinski A. [Tetanus in Poland in 2004]. Przegl Epidemiol 2006;60:487-489.
19. Zielinski A. [Tetanus in 2005]. Przegl Epidemiol 2007;61: 287-289.
20. Zielinski A. [Tetanus in Poland in 2006]. Przegl Epidemiol 2008;62:333-335.
21. Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J 2007;26:806-810.
22. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002;347:340-346.
23. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007;356:1338-1343.
24. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.
25. United Nations. World population ageing 1950-2050. In: Affairs DoEaS, ed. United Nations, 2002.
26. Michel JP, Gold G. Coping with population aging in the old continent-the need for european academic geriatrics. J Gerontol A Biol Sci Med Sci 2001;56:M341-M343.
27. Thiry E, Horzinek MC. Vaccination guidelines: A bridge between official requirements and the daily use of vaccines. Rev Sci Tech 2007;26:511-517.
28. World Health Organization. Resolution 56.19; 23 May. World Health Organization, Geneva, 2003.
29. European Parliament. [P6 - TA (2005) 0406] 26 October. Brussels: European Community, 2005.
30. Stuck AE, Kharicha K, Dapp U et al. Development, feasibility and performance of a health risk appraisal questionnaire for older persons. BMC Med Res Methodol 2007;7:1.
31. Noakes K, Pebody RG, Gungabissoon U, Stowe J, Miller E. Pneumococcal polysaccharide vaccine uptake in England, 1989-2003, prior to the introduction of a vaccination programme for older adults. J Public Health (Oxf) 2006;28:242-247.
32. Gavazzi G, Wazieres B, Lejeune B, Rothan-Tondeur M. Influenza and pneumococcal vaccine coverages in geriatric health care settings in France. Gerontology 2007;53:144-149.
33. Montrieux C, Collette G, Limme C, Seidel L, Albert A, Giet D. [Evaluation of tetanus vaccine coverage in rural society]. Rev Med Liege 2002;57:97-103.
34. Guthmann JP FL, Antona D et Lévy-Bruhl D. [Couverture vaccinale diphtérie, tétanos, poliomyélite chez l'adulte en France: résultats de l'enquête santé et Protection Sociale, 2002]. Bull Epidemiol Hebdomadaire 2007;51-52, 441-445.
35. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159-1169.
36. Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999;67:5979-5984.
37. Bayas JM, Vilella A, Bertran MJ et al. Immunogenicity and reactogenicity of the adult tetanus-diphtheria vaccine. How many doses are necessary? Epidemiol Infect 2001;127:451-460.
38. Stubbe M, Swinnen R, Crusiaux A, Mascart F, Lheureux PE. Seroprotection against tetanus in patients attending an emergency department in Belgium and evaluation of a bedside immunotest. Eur J Emerg Med 2007;14:14-24.
39. Van Damme P, Burgess M. Immunogenicity of a combined diphtheria-tetanus- acellular pertussis vaccine in adults. Vaccine 2004;22:305-308.
40. Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine 2001;20:121-124.
41. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;82:1341-1349.
42. Gnann JW, Jr. Vaccination to prevent herpes zoster in older adults. J Pain 2008;9:S31-S36.
43. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 2005;165:265-272.
44. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007;7:658-666.
45. Mangtani P, Cumberland P, Hodgson CR, Roberts JA, Cutts FT, Hall AJ. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 2004; 190:1-10.
46. Vila-Corcoles A, Rodriguez T, de Diego C et al. Effect of influenza vaccine status on winter mortality in Spanish community-dwelling elderly people during 2002-2005 influenza periods. Vaccine 2007;25:6699-6707.
47. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002;20:1831-1836.
48. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007;357:1373-1381.
49. Gaillat J, Zmirou D, Mallaret MR et al. [Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions]. Rev Epidemiol Sante Publique 1985;33:437-444.
50. Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-2284.
51. Romero-Steiner S, Musher DM, Cetron MS et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999; 29:281-288.
52. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007;357:1903-1915.
53. Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med 2007;9:1-17.
54. Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007;25:3066-3069.
55. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence: Is it infectious? Immunol Rev 2005;205:257-268.
56. Fulop T, Larbi A, Wikby A, Mocchegiani E, Hirokawa K, Pawelec G. Dysregulation of T-cell function in the elderly: Scientific basis and clinical implications. Drugs Aging 2005;22:589-603.
57. Pfister G, Weiskopf D, Lazuardi L et al. Naive T cells in the elderly: Are they still there? Ann N Y Acad Sci 2006;1067: 152-157.
58. Saurwein-Teissl M, Lung TL, Marx F et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002;168:5893-5899.
59. Chiu WK, Fann M, Weng NP. Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines. J Immunol 2006;177:7802-7810.
60. Schwaiger S, Wolf AM, Robatscher P, Jenewein B, Grubeck-Loebenstein B. IL-4-producing CD8+ T cells with a CD62L++(bright) phenotype accumulate in a subgroup of older adults and are associated with the maintenance of intact humoral immunity in old age. J Immunol 2003;170: 613-619.
61. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004;59:255-263.
62. Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007;25:3871-3878.
63. Guebre-Xabier M, Hammond SA, Ellingsworth LR, Glenn GM. Immunostimulant patch enhances immune responses to influenza virus vaccine in aged mice. J Virol 2004;78: 7610-7618.
64. Frech SA, Kenney RT, Spyr CA et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005;23:946-950.
65. Glenn GM, Kenney RT. Mass vaccination: Solutions in the skin. Curr Top Microbiol Immunol 2006;304:247-268.
66. Weycker D, Edelsberg J, Halloran ME et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine 2005;23:1284-1293.
67. Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe. Euro Surveill 2005;10:174-178.
68. Ridda I, MacIntyre RC, Lindley RI et al. Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded national pneumococcal vaccination program in Australia. Hum Vaccin 2007;3:83-86.
69. Lobanov A. Immunization programme in the European region: Progress and challenges. WHO: http://www.worldbank.org/eca/presentations/ecshd/2006/,2006.
70. Cortese MM, Baughman AL, Brown K, Srivastava P. A "new age" in pertussis prevention new opportunities through adult vaccination. Am J Prev Med 2007;32:177-185.
71. Hu JJ, Lu CY, Chang LY et al. Survey of pertussis in patients with prolonged cough. J Microbiol Immunol Infect 2006; 39:54-58.
72. Huang Y, Rohani P. Age-structured effects and disease interference in childhood infections. Proc Biol Sci 2006;273: 1229-1237.
73. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24:S58-S61.
74. Forsyth KD, Wirsing von Konig CH, Tan T, Caro J, Plotkin S. Prevention of pertussis: Recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007;25:2634-2642.
75. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004;23:363-368.
76. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA 1999;96:14001-14006.
77. Nicholson KG. Socioeconomics of influenza and influenza vaccination in Europe. Pharmacoeconomics 1996;9(Suppl 3):75-78.
78. Patel MS, Davis MM. Could a federal program to promote influenza vaccination among elders be cost-effective? Prev Med 2006;42:240-246.
79. Nichol KL, Nordin J, Mullooly J. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons. Vaccine 2006;24:1562-1568.
80. Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: Results of a systematic review and analysis. Am J Prev Med 2006;31:52-61.
81. Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine 2006; 24:1035-1043.
82. Prosser LA, O'Brien MA, Molinari NA, et al. Non-traditional settings for influenza vaccination of adults: Costs and cost effectiveness. Pharmacoeconomics 2008;26:163-178.
83. Evers SM, Ament AJ, Colombo GL et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: An update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007;26:531-540.
84. Lee GM, Murphy TV, Lett S et al. Cost effectiveness of pertussis vaccination in adults. Am J Prev Med 2007;32:186-193.
85. Lee GM, Riffelmann M, Wirsing von Konig CH. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine 2008;26:3673-3679.
86. Brisson M, Pellissier JM, Levin MJ. Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy 134 MICHEL ET AL. against postherpetic neuralgia. Clin Infect Dis 2007;45:1527-1529.
87. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007;44:1280-1308.
88. Lieu TA, Ortega-Sanchez I, Ray GT et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008;26:235-249.
89. Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med 2008;121:S28-S35.
90. Kotchen TA. Why the slow diffusion of treatment guidelines into clinical practice? Arch Intern Med 2007;167:2394-2395.